New drug strategy aims to keep aggressive head and neck cancer at bay
NCT ID NCT02769520
Summary
This study is testing if adding the immunotherapy drug pembrolizumab after repeat surgery can help people with recurrent head and neck cancer stay cancer-free for longer. It involves about 45 participants whose cancer has come back in the same area. Some patients will receive the drug before their surgery to help researchers understand how it affects the immune system around the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Los Angeles
Torrance, California, 90505, United States
-
University of California San Francisco
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.